Navigation Links
STERIS Corporation Announces Fiscal 2009 Second Quarter and First Half Results
Date:10/30/2008

MENTOR, Ohio, Oct. 30 /PRNewswire-FirstCall/ -- STERIS Corporation (NYSE: STE) today announced financial results for its fiscal 2009 second quarter ended September 30, 2008. Fiscal 2009 second quarter revenues increased 10% to $323.1 million compared with $295.0 million in the second quarter of fiscal 2008, driven by strong growth in all three business segments. Fiscal 2009 second quarter net income was $28.8 million, or $0.48 per diluted share, compared with net income of $16.0 million, or $0.25 per diluted share, in the second quarter of fiscal 2008. Net income growth was a result of increased volumes, higher gross margins, improved operating expense leverage and the sale of an Isomedix facility in the Chicago area during the quarter.

For the first half of fiscal 2009, revenues increased 10% to $634.7 million compared with $575.9 million in the first half of fiscal 2008. Net income for the first half of fiscal 2009 was $54.3 million, or $0.90 per diluted share, compared with net income of $29.2 million, or $0.45 per diluted share in the first half of fiscal 2008.

"STERIS has had a strong start to this fiscal year, with double-digit revenue growth and solid earnings performance in the first half of the year," said Walt Rosebrough, President and Chief Executive Officer of STERIS. "We are pleased to see our strategies taking hold, with new products contributing nicely to our growth and cost reduction efforts driving operating leverage. As we look out at the remainder of the year, we anticipate that our growth rates will moderate compared with first half levels, driven in part by our efforts to reduce the historic seasonality in our business in order to level out our production. In addition, the current political and economic uncertainties cause us to remain somewhat conservative about our performance for the balance of this year."

Quarterly Segment Results

Healthcare revenues in the quarter increased 10% to $227.8 million compared with the second quarter of fiscal 2008. In particular, sales of capital equipment increased 14%, driven in part by increased demand for the Company's new product offerings. Consumables and service also reported strong growth in the quarter of 7% each compared to the prior year. Order backlog levels at quarter end were a record $124.1 million. Operating income was $32.7 million, an increase of 51% compared with the prior year period, driven by increased volumes, higher gross margins and improved operating expense leverage.

Life Sciences second quarter revenues were $57.2 million, an increase of 9% compared with the second quarter of fiscal 2008. Revenue growth was primarily driven by an increase in capital equipment sales of 17%, as well as an 8% improvement in consumables compared with the prior year quarter. Order backlog declined 16% to $48.7 million compared with the prior year period. Life Sciences operating income was $6.2 million in the quarter compared with $3.4 million in the second quarter of fiscal 2008. Operating income benefited from increased volumes and improved operating expense leverage.

Fiscal 2009 second quarter revenues for Isomedix Services were $37.0 million, an increase of 6% compared with the same period last year. Revenue growth was driven by increased demand from medical device Customers and modest pricing improvements to offset increased costs. Operating income was $10.2 million compared with $7.1 million in the prior year quarter. During the second quarter, Isomedix completed the sale of a facility located in the Chicago area to a privately-held Customer, which added $2.1 million to operating income during the quarter.

Cash Flow

Net cash provided by operations and free cash flow (see note 1) for the first half of fiscal 2009 were $68.8 million and $57.3 million, respectively. These compare favorably with $53.2 million and $31.6 million in the same period last year, primarily reflecting the increase in earnings and the impact of the Isomedix facility sale, which added $9.5 million to free cash flow.

During the second quarter and through October 29, 2008, the Company repurchased 1,065,277 shares of its common stock at an average price of $33.78 per common share for a total amount of $36.0 million. Approximately $217 million remains under the current share repurchase authorization.

Outlook

Based upon first half performance and current anticipated trends in the second half of the year, the Company is updating its outlook for fiscal 2009. The Company currently anticipates revenue growth for the full year to be toward the high-end of the previously announced range of 4-6%. Earnings may exceed the high-end of the previously announced range by as much as $0.15, potentially resulting in earnings per diluted share of up to $1.80 for the full year. This outlook reflects certain assumptions and is subject to numerous uncertainties, some of which are listed below:

-- Revenue growth is expected to be in the high single digits in Healthcare, and in the low single digits for both Life Sciences and Isomedix.

-- The Company is assuming that the recent strength in the United States dollar will not hold relative to international currencies.

-- The Company is assuming a modest increase in material costs in the second half of the year compared with the first half of the fiscal year.

-- Operating margin is currently anticipated to be approximately 12.5% for the full year.

-- The anticipated effective tax rate is approximately 35% for the full year.

For the full year, free cash flow (see note 1) is now anticipated to be approximately $100 million, reflecting the sale of the Isomedix facility during the second quarter. Capital expenditures are anticipated to be approximately $55 million.

Conference Call

In conjunction with this press release, STERIS Corporation management will host a conference call today at 10:00 a.m. Eastern time. The conference call can be heard live over the Internet at http://www.steris-ir.com or via phone by dialing 1-888-392-9976 in the United States and Canada, and 1-517-645-6486 internationally, then referencing the password "STERIS" and the conference leader's name, "Julie Winter."

For those unable to listen to the conference call live, a replay will be available from 12:00 p.m. Eastern time on October 30, 2008, until 5:00 p.m. Eastern time on November 13, 2008, either over the Internet at http://www.steris-ir.com or via phone by calling 1-800-756-3940 in the United States and Canada, and 1-402-998-0796 internationally.

About STERIS

STERIS Corporation is a leading provider of infection prevention and surgical products and services, focused primarily on the critical markets of healthcare, pharmaceutical and research. The Company's more than 5,000 dedicated employees around the world work together to supply a broad array of solutions by offering a combination of equipment, consumables and services that enhance Customer productivity and quality, and help make the world a safer place. The Company is listed on the New York Stock Exchange under the symbol STE. For more information, visit http://www.steris.com .

(1) Free cash flow is a non-GAAP number used by the Company as a measure to gauge its ability to fund future growth opportunities, repurchase common shares, and pay cash dividends. Free cash flow is defined as cash flows from operating activities less purchases of property, plant, equipment and intangibles, net, plus proceeds from the sale of property, plant, equipment and intangibles. STERIS's calculation of free cash flow may vary from other companies.

This news release, and the conference call referenced here, may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to the Company or its industry that are intended to qualify for the protections afforded "forward-looking statements" under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date of this report, and may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "targets," "forecasts," "potential," "confidence," and "seeks," or the negative of such terms or other variations on such terms or comparable terminology. Many important factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, disruption of production or supplies, changes in market conditions, political events, pending or future claims or litigation, competitive factors, technology advances, actions of regulatory agencies, and changes in government regulations or the application or interpretation thereof. Other risk factors are described in the Company's Form 10-K and other securities filings. Many of these important factors are outside STERIS's control. No assurances can be provided as to any outcome from litigation, regulatory action, administrative proceedings, government investigations, warning letters, cost reductions, business strategies, level of share repurchases, earnings and revenue trends, expense reduction or other future financial results. Unless legally required, the Company does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized. Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, (a) the potential for increased pressure on pricing that leads to erosion of profit margins, (b) the possibility that market demand will not develop for new technologies, products or applications, or the Company's business initiatives will take longer, cost more or produce lower benefits than anticipated, (c) the possibility that application of or compliance with laws, court rulings, regulations, regulatory actions, including without limitation the previously disclosed FDA warning letter, certifications or other requirements or standards may delay or prevent new product introductions, affect the production and marketing of existing products, or otherwise affect Company performance, results, or value, (d) the potential of international unrest or effects of fluctuations in currencies, tax assessments or rates, raw material costs, benefit or retirement plan costs, or other regulatory compliance costs, (e) the possibility of reduced demand, or reductions in the rate of growth in demand, for the Company's products and services, (f) the possibility that anticipated cost savings or other results may not be achieved, or that transition, labor, competition, timing, execution, regulatory, governmental, or other issues or risks associated with the matters described in this release, and the conference call referenced here, may adversely impact Company performance, results, or value, (g) the effect of the credit crisis on our ability, as well as the ability of our customers and suppliers, to adequately access the credit markets when needed, and (h) those risks described in our Annual Report on Form 10-K for the year ended March 31, 2008, filed with the SEC on May 30, 2008, under Item 1A, "Risk Factors."

STERIS Corporation

Consolidated Condensed Statements of Income

(In thousands, except per share data)

Three Months Ended Six Months Ended

September 30, September 30,

2008 2007 2008 2007

(Unaudited) (Unaudited) (Unaudited) (Unaudited)

Revenues $323,127 $295,002 $634,692 $575,946

Cost of revenues 190,764 174,794 371,828 340,138

Gross profit 132,363 120,208 262,864 235,808

Operating expenses:

Selling, general,

and administrative 77,290 84,531 164,638 167,914

Research and

development 8,068 8,531 16,347 17,790

Restructuring expense 37 698 (129) 2,089

Total operating expenses 85,395 93,760 180,856 187,793

Income from operations 46,968 26,448 82,008 48,015

Non-operating

expense, net 1,978 864 3,363 1,637

Income tax expense 16,196 9,566 24,351 17,157

Net income $28,794 $16,018 $54,294 $29,221

Earnings per common

share (EPS) data:

Basic $0.49 $0.25 $0.92 $0.45

Diluted $0.48 $0.25 $0.90 $0.45

Cash dividends declared

per common share

outstanding $0.08 $0.06 $0.14 $0.11

Weighted average number

of common shares

outstanding used in

EPS computation:

Basic number of

common shares

outstanding 59,312 64,207 59,003 64,612

Diluted number of

common shares

outstanding 60,376 65,047 60,012 65,478

STERIS Corporation

Consolidated Condensed Balance Sheets

(In thousands)

September 30, March 31,

2008 2008

Assets (Unaudited)

Current assets:

Cash and cash equivalents $160,219 $51,868

Accounts receivable, net 210,997 249,814

Inventories, net 161,298 147,210

Other current assets 46,124 64,484

Total Current Assets 578,638 513,376

Property, plant, and equipment, net 371,327 384,642

Goodwill and intangible assets, net 321,120 337,980

Other assets 3,564 3,294

Total Assets $1,274,649 $1,239,292

Liabilities and Shareholders' Equity

Current liabilities:

Accounts payable $65,684 $75,532

Other current liabilities 119,905 154,827

Total Current Liabilities 185,589 230,359

Long-term debt 250,000 179,280

Other liabilities 94,310 123,501

Shareholders' equity 744,750 706,152

Total Liabilities and Shareholders' Equity $1,274,649 $1,239,292

STERIS Corporation

Segment Data

(In thousands)

Three Months Ended Six Months Ended

September 30, September 30,

2008 2007 2008 2007

(Unaudited) (Unaudited) (Unaudited) (Unaudited)

Segment Revenues:

Healthcare $227,836 $206,684 $451,901 $402,375

Life Sciences 57,151 52,323 105,190 99,025

STERIS Isomedix Services 36,971 34,793 73,834 70,265

Total Reportable

Segments 321,958 293,800 630,925 571,665

Corporate and Other 1,169 1,202 3,767 4,281

Total Segment Revenues $323,127 $295,002 $634,692 $575,946

Segment Operating Income (Loss):

Healthcare $32,698 $21,598 $61,928 $39,530

Life Sciences 6,228 3,369 7,275 3,638

STERIS Isomedix Services 10,211 7,081 18,398 14,802

Total Reportable

Segments 49,137 32,048 87,601 57,970

Corporate and Other (2,169) (5,600) (5,593) (9,955)

Total Segment Operating

Income $46,968 $26,448 $82,008 $48,015

STERIS Corporation

Consolidated Condensed Statements of Cash Flows

(In thousands)

Six Months Ended

September 30,

2008 2007

(Unaudited) (Unaudited)

Operating Activities:

Net income $54,294 $29,221

Non-cash items 34,607 33,791

Working capital adjustments (20,210) (9,844)

Net cash provided by operating activities 68,691 53,168

Investing Activities:

Purchases of property, plant,

equipment, and intangibles, net (20,872) (21,591)

Proceeds from sale of property,

plant, equipment and intangibles 9,506 31

Net cash used in investing activities (11,366) (21,560)

Financing Activities:

Proceeds from the issuance of

long-term obligations 150,000 -

(Payments) proceeds under credit

facilities, net (79,180) 24,090

Deferred financing fees and debt

issuance costs (476) (443)

Repurchases of common shares (50,210) (54,476)

Cash dividends paid to common

shareholders (8,275) (7,112)

Stock options and other equity

transactions, net 41,688 13,008

Net cash provided by (used in)

financing activities 53,547 (24,933)

Effect of exchange rate changes on

cash and cash equivalents (2,521) 2,592

Increase in cash and cash

equivalents 108,351 9,267

Cash and cash equivalents at

beginning of period 51,868 52,296

Cash and cash equivalents at end of

period $160,219 $61,563

Six Months Ended

September 30,

2008 2007

(Unaudited) (Unaudited)

Calculation of Free Cash Flow from

continuing operations:

Cash flows from operating activities $68,691 $53,168

Purchases of property, plant,

equipment, and intangibles, net (20,872) (21,591)

Proceeds from the sale of property,

plant, equipment, and intangibles 9,506 31

Free Cash Flow from Continuing Operations $57,325 $31,608

Free cash flow is defined by the Company as cash flows from operating

activities less purchases of property, plant, equipment and intangibles,

net (capital expenditures) plus proceeds from the sale of property, plant,

equipment and intangibles. Free cash flow is a non-GAAP figure under

Securities and Exchange Commission rules. The Company uses free cash flow

as a measure to gauge its ability to fund future growth opportunities,

repurchase common shares, and pay cash dividends. STERIS's calculation of

free cash flow may vary from other companies.


'/>"/>
SOURCE STERIS Corporation
Copyright©2008 PR Newswire.
All rights reserved


Related biology technology :

1. Hospitals Adopt STERIS Advanced Room Sterilization Technology in the Fight Against Superbugs
2. MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 5, 2008
3. Waters Corporation Gives Boost to Clinical Research Programs at University of Sherbrooke Hospital
4. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
5. Environmental Tectonics Corporations BioMedical Systems Division Places Two Monoplace Chambers at East Orange (NJ) General Hospital
6. International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees
7. Techne Corporation Declares Dividend
8. LI-COR Biosciences and Euthanex Corporation Provide Anesthesia System for Small Animal Imaging
9. Techne Corporation Releases Unaudited First Quarter Results for Fiscal Year 2009
10. Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles
11. Baxa Corporation Features PadLock(R) Set Saver at the ANCC National Magnet Conference(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... ... February 04, 2016 , ... ... Forensics Club, takes place February 5-6 at the University’s student center, Kehr ... activities such as workshops and competitions for ample networking, learning and collaborating ...
(Date:2/4/2016)... and MENLO PARK, Calif. , Feb. ... ("DelMar" and the "Company"), a biopharmaceutical company focused on the ... it will present at the 18 th Annual ... 2016 at 10:00 a.m. EST in New York, ... president and CEO, will provide an update on the ongoing ...
(Date:2/4/2016)...  Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual property ... intellectual property, today provided an update on the Company,s ... of Texas and announcing that ... Partes Re-examination ("IPR") proceedings that VTech and Uniden ... initiated on only certain claims of two of the ...
(Date:2/4/2016)... 4, 2016 Strasbourg, France ... --> Strasbourg, France , to the ... PharmaVentures is pleased to announce that it acted as an ... unit in Strasbourg, France , to the ... --> --> Transgene (Euronext: TNG), a member ...
Breaking Biology Technology:
(Date:2/3/2016)... , February 4, 2016 --> ... to SEK 1,351.5 M (105.0), up 1,187% compared with fourth quarter of ... amounted to SEK 517.6 M (loss: 30.0). Earnings per share ... activities was SEK 537.4 M (neg: 74.7). , ... , Revenues amounted to SEK 2,900.5 M (233.6), up 1,142% compared with ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 /PRNewswire/ ... analysis of the bioinformatic market by reviewing the ... computer enabled tools that drive the field forward. ... report to: Identify the challenges and opportunities ... service providers and software solution developers, as well ...
(Date:2/1/2016)... 1, 2016 Rising sales of ... global touchfree intuitive gesture control market size ... sales of consumer electronics coupled with new technological advancements ... size through 2020   --> ... new technological advancements to drive global touchfree intuitive gesture ...
Breaking Biology News(10 mins):